Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit convinced a federal judge that unexpected results and industry skepticism supported the validity of an Invega Sustenna patent, beating remanded challenges by two generic-drug makers that had conceded infringement.
Teva Pharmaceutical Industries Ltd.'s arguments that the patent is invalid, which were considered as being presented by both Teva and Viatris Inc.’s Mylan Laboratories Ltd. unit, “are unsupported by the record, contradicted by the prior art and inconsistent with its own expert’s testimony,” Judge Claire C. Cecchi wrote in an opinion unsealed Dec. 17 in the US District Court for the District of New ...
